Becton Dickinson and Co (NYSE:BDX) CEO Vincent A. Forlenza sold 19,675 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $275.15, for a total transaction of $5,413,576.25. Following the sale, the chief executive officer now owns 227,647 shares in the company, valued at approximately $62,637,072.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NYSE BDX traded up $0.24 on Friday, hitting $273.78. The stock had a trading volume of 630,820 shares, compared to its average volume of 1,074,478. Becton Dickinson and Co has a one year low of $221.47 and a one year high of $275.54. The company has a quick ratio of 0.72, a current ratio of 1.18 and a debt-to-equity ratio of 0.86. The stock has a market cap of $73.94 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.07. The company’s 50-day moving average is $265.04 and its two-hundred day moving average is $255.28.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping the consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The firm had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter in the prior year, the firm earned $2.93 EPS. Becton Dickinson and’s quarterly revenue was up 4.1% on a year-over-year basis. On average, sell-side analysts anticipate that Becton Dickinson and Co will post 12.57 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th were given a $0.79 dividend. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. This represents a $3.16 annualized dividend and a yield of 1.15%. Becton Dickinson and’s dividend payout ratio is 27.05%.

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Stifel Nicolaus increased their price objective on shares of Becton Dickinson and from $275.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Barclays lowered shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective on the stock. in a research note on Wednesday. KeyCorp dropped their price objective on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Finally, Morgan Stanley upped their target price on shares of Becton Dickinson and from $261.00 to $287.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $277.70.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisors Capital Management LLC boosted its holdings in shares of Becton Dickinson and by 5.9% in the fourth quarter. Advisors Capital Management LLC now owns 88,034 shares of the medical instruments supplier’s stock valued at $23,943,000 after acquiring an additional 4,896 shares in the last quarter. Chesley Taft & Associates LLC boosted its holdings in shares of Becton Dickinson and by 26.8% in the fourth quarter. Chesley Taft & Associates LLC now owns 5,061 shares of the medical instruments supplier’s stock valued at $1,376,000 after acquiring an additional 1,070 shares in the last quarter. Bath Savings Trust Co boosted its holdings in shares of Becton Dickinson and by 4.2% in the fourth quarter. Bath Savings Trust Co now owns 31,987 shares of the medical instruments supplier’s stock valued at $8,699,000 after acquiring an additional 1,289 shares in the last quarter. JGP Wealth Management LLC boosted its holdings in shares of Becton Dickinson and by 13.0% in the fourth quarter. JGP Wealth Management LLC now owns 12,706 shares of the medical instruments supplier’s stock valued at $3,474,000 after acquiring an additional 1,466 shares in the last quarter. Finally, Mitchell Sinkler & Starr PA bought a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $201,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is the Shanghai Stock Exchange Composite Index?

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.